apceth™-301 are genetically engineered MSC which express a potent “cocktail” of proinflammatory cytokines that locally activates the patient’s immune system to eradicate cancer cells.
apceth™-301 stimulates tumor immune response to recognize and destroy cancer cells by:
- increasing IFN-γ production,
- activating macrophages and NK-cells,
- activating T-cells,
- promoting long term antitumor immunity similar to cancer vaccine.
apceth™-301 is currently being developed for Glioblastoma multiforme, as well as for other solid tumors.
apceth™-301 has also shown promising synergetic effects when combined to CAR-T cell therapies.